Trial Profile
A Single-Center, Retrospective, Observational Study Assessing the Association of Total Tumor Burden (TBT) with Clinical Outcomes of Metastatic Melanoma Patients Treated with Nivolumab
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 Jun 2017
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 13 Jun 2017 New trial record
- 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.